Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer

類似資料

• Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
  著者:: Cui, Shaohua, 等
  出版事項: (2016)
• Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
  著者:: Liu, Jun, 等
  出版事項: (2018)
• Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors
  著者:: Cui, Shaohua, 等
  出版事項: (2016)
• Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
  著者:: Xiong, Liwen, 等
  出版事項: (2017)
• ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
  著者:: Dacic, Sanja, 等
  出版事項: (2016)